193 related articles for article (PubMed ID: 28540987)
1. Lack of Aberrant Methylation in an Adjacent Area of Left-Sided Colorectal Cancer.
Sambuudash O; Kim HS; Cho MY
Yonsei Med J; 2017 Jul; 58(4):749-755. PubMed ID: 28540987
[TBL] [Abstract][Full Text] [Related]
2. Molecular dissection of premalignant colorectal lesions reveals early onset of the CpG island methylator phenotype.
Yamamoto E; Suzuki H; Yamano HO; Maruyama R; Nojima M; Kamimae S; Sawada T; Ashida M; Yoshikawa K; Kimura T; Takagi R; Harada T; Suzuki R; Sato A; Kai M; Sasaki Y; Tokino T; Sugai T; Imai K; Shinomura Y; Toyota M
Am J Pathol; 2012 Nov; 181(5):1847-61. PubMed ID: 22995252
[TBL] [Abstract][Full Text] [Related]
3. TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer.
Ogino S; Kawasaki T; Ogawa A; Kirkner GJ; Loda M; Fuchs CS
Hum Pathol; 2007 Apr; 38(4):614-20. PubMed ID: 17270239
[TBL] [Abstract][Full Text] [Related]
4. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency.
Dawson H; Galván JA; Helbling M; Muller DE; Karamitopoulou E; Koelzer VH; Economou M; Hammer C; Lugli A; Zlobec I
Int J Cancer; 2014 May; 134(10):2342-51. PubMed ID: 24166180
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features.
Zlobec I; Bihl M; Foerster A; Rufle A; Lugli A
J Pathol; 2011 Nov; 225(3):336-43. PubMed ID: 21660972
[TBL] [Abstract][Full Text] [Related]
6. MGMT promoter methylation and field defect in sporadic colorectal cancer.
Shen L; Kondo Y; Rosner GL; Xiao L; Hernandez NS; Vilaythong J; Houlihan PS; Krouse RS; Prasad AR; Einspahr JG; Buckmeier J; Alberts DS; Hamilton SR; Issa JP
J Natl Cancer Inst; 2005 Sep; 97(18):1330-8. PubMed ID: 16174854
[TBL] [Abstract][Full Text] [Related]
7. Promoter methylation of specific genes is associated with the phenotype and progression of colorectal adenocarcinomas.
Kim JC; Choi JS; Roh SA; Cho DH; Kim TW; Kim YS
Ann Surg Oncol; 2010 Jul; 17(7):1767-76. PubMed ID: 20077021
[TBL] [Abstract][Full Text] [Related]
8. The CpG island methylator phenotype correlates with long-range epigenetic silencing in colorectal cancer.
Karpinski P; Ramsey D; Grzebieniak Z; Sasiadek MM; Blin N
Mol Cancer Res; 2008 Apr; 6(4):585-91. PubMed ID: 18403637
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of p21 (CDKN1A/CIP1) is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer.
Ogino S; Kawasaki T; Kirkner GJ; Ogawa A; Dorfman I; Loda M; Fuchs CS
J Pathol; 2006 Oct; 210(2):147-54. PubMed ID: 16850502
[TBL] [Abstract][Full Text] [Related]
10. Distinct features between MLH1-methylated and unmethylated colorectal carcinomas with the CpG island methylator phenotype: implications in the serrated neoplasia pathway.
Kim JH; Bae JM; Cho NY; Kang GH
Oncotarget; 2016 Mar; 7(12):14095-111. PubMed ID: 26883113
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.
Lee S; Cho NY; Choi M; Yoo EJ; Kim JH; Kang GH
Pathol Int; 2008 Feb; 58(2):104-13. PubMed ID: 18199160
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive methylation analysis of imprinting-associated differentially methylated regions in colorectal cancer.
Hidaka H; Higashimoto K; Aoki S; Mishima H; Hayashida C; Maeda T; Koga Y; Yatsuki H; Joh K; Noshiro H; Iwakiri R; Kawaguchi A; Yoshiura KI; Fujimoto K; Soejima H
Clin Epigenetics; 2018 Dec; 10(1):150. PubMed ID: 30509319
[TBL] [Abstract][Full Text] [Related]
13. Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points.
O'Brien MJ; Yang S; Mack C; Xu H; Huang CS; Mulcahy E; Amorosino M; Farraye FA
Am J Surg Pathol; 2006 Dec; 30(12):1491-501. PubMed ID: 17122504
[TBL] [Abstract][Full Text] [Related]
14. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies.
Ogino S; Cantor M; Kawasaki T; Brahmandam M; Kirkner GJ; Weisenberger DJ; Campan M; Laird PW; Loda M; Fuchs CS
Gut; 2006 Jul; 55(7):1000-6. PubMed ID: 16407376
[TBL] [Abstract][Full Text] [Related]
15. Relative role of methylator and tumor suppressor pathways in ulcerative colitis-associated colon cancer.
Sanchez JA; Dejulius KL; Bronner M; Church JM; Kalady MF
Inflamm Bowel Dis; 2011 Sep; 17(9):1966-70. PubMed ID: 21618350
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling.
Hinoue T; Weisenberger DJ; Pan F; Campan M; Kim M; Young J; Whitehall VL; Leggett BA; Laird PW
PLoS One; 2009 Dec; 4(12):e8357. PubMed ID: 20027224
[TBL] [Abstract][Full Text] [Related]
17. CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations.
Ogino S; Kawasaki T; Kirkner GJ; Loda M; Fuchs CS
J Mol Diagn; 2006 Nov; 8(5):582-8. PubMed ID: 17065427
[TBL] [Abstract][Full Text] [Related]
18. Distinct CpG island methylation profiles and BRAF mutation status in serrated and adenomatous colorectal polyps.
Kim YH; Kakar S; Cun L; Deng G; Kim YS
Int J Cancer; 2008 Dec; 123(11):2587-93. PubMed ID: 18798261
[TBL] [Abstract][Full Text] [Related]
19. CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer.
Zhang X; Shimodaira H; Soeda H; Komine K; Takahashi H; Ouchi K; Inoue M; Takahashi M; Takahashi S; Ishioka C
Int J Clin Oncol; 2016 Dec; 21(6):1091-1101. PubMed ID: 27435270
[TBL] [Abstract][Full Text] [Related]
20. CpG island methylation is frequently present in tubulovillous and villous adenomas and correlates with size, site, and villous component.
Kakar S; Deng G; Cun L; Sahai V; Kim YS
Hum Pathol; 2008 Jan; 39(1):30-6. PubMed ID: 17950780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
